FDA's June 2026 Warning Letters Reveal New Compliance Risks For Telehealth GLP-1 Marketing

Executive Summary

The U.S. Food and Drug Administration (FDA) issued a new wave of warning letters in June 2026 targeting telehealth companies marketing compounded GLP-1 medications.

After reviewing multiple warning letters, several recurring themes emerged surrounding how compounded semaglutide and tirzepatide products are marketed online. While each warning letter addressed individual companies, the findings reveal consistent areas of regulatory focus. This report summarizes those publicly available FDA findings.

What Triggered The FDA Warning Letters?

According to the warning letters, the FDA reviewed company websites offering compounded semaglutide and compounded tirzepatide products. The agency determined that certain website claims and promotional representations violated sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) relating to false or misleading promotion.

The FDA stated that the cited violations may result in compounded products being considered misbranded. The warning letters repeatedly referenced Section 502(a) and Section 502(bb) of the FD&C Act.

Key Theme #1: Compounded Drugs Are Not FDA Approved

One of the most consistent statements across the warning letters was that compounded medications are not FDA-approved drugs. The FDA repeatedly emphasized that compounded drugs do not undergo FDA premarket review for:

• ✓Safety
• ✓Effectiveness
• ✓Quality

The agency also reminded companies that compounded drugs are different from FDA-approved medications and are subject to separate regulatory requirements.

Key Theme #2: Comparisons To FDA-Approved Medications Were Frequently Cited

Several warning letters cited statements that compared compounded products to FDA-approved drugs. Examples published by the FDA included:

• ✓"Same active ingredient as Ozempic®"
• ✓"Same active ingredient as Wegovy®"
• ✓"Access to the same active ingredient found in Ozempic®"

The FDA stated these representations were false or misleading because they may imply that compounded products have been evaluated or approved in the same manner as FDA-approved medications.

Key Theme #3: Clinical Efficacy Language Received Increased Scrutiny

The FDA also cited claims suggesting that compounded products had established clinical validation. Examples included:

• ✓"Clinically studied ingredients"
• ✓"Clinically studied to help patients"
• ✓"Clinically proven weight loss"
• ✓"Proven to lose weight effectively"

The warning letters state that compounded drugs are not FDA-approved products and have not undergone FDA evaluation for safety and effectiveness. The FDA concluded that these statements may create misleading impressions regarding the products being marketed.

Key Theme #4: Company Branding On Medication Labels Was Cited

Several warning letters referenced images displayed on company websites. In these examples, medication labels contained the telehealth company's own brand name.

According to the FDA, this may falsely suggest that the telehealth company itself is the compounder or manufacturer of the medication. The FDA cited existing labeling regulations supporting this position.

Key Theme #5: "FDA Approved" Or "FDA Licensed" Pharmacy Claims Were Cited

Multiple warning letters addressed statements involving pharmacy sourcing. Examples included:

• ✓"FDA approved pharmacies"
• ✓"FDA licensed facilities"
• ✓"FDA approved facilities"

The FDA explicitly stated that these designations do not exist for compounding pharmacies or outsourcing facilities. The agency explained that neither pharmacies nor outsourcing facilities receive FDA approval or FDA licensure designations. According to the FDA, these statements may falsely imply government authorization.

What The FDA Requested Companies To Do

The warning letters instructed companies to respond within 15 business days. The FDA requested that companies:

1. 1.
   Identify the producing entities

   Identify the entities producing the compounded products offered on their websites.

2. 2.
   Provide representative labeling

   Provide representative product labeling.

3. 3.
   Address misleading claims

   Address, modify, or remove false or misleading claims.

The FDA also requested explanations describing how companies would prevent future violations.

Why These Warning Letters Matter

These warning letters provide visibility into current FDA enforcement priorities involving compounded GLP-1 marketing. The FDA specifically reviewed publicly available website content and promotional representations when issuing these letters.

The findings also demonstrate that the agency is closely examining how compounded medications are described to consumers.

Conclusion

The June 2026 FDA warning letters repeatedly focused on five categories of claims:

• ✓Comparisons to FDA-approved drugs
• ✓Clinical efficacy statements
• ✓Company branding on medication labels
• ✓FDA approval or licensure statements
• ✓Promotional language that may create false or misleading impressions

As the telehealth industry continues to grow, these publicly available warning letters offer insight into how the FDA is currently evaluating the online promotion of compounded GLP-1 products.

Sources

• FDA Warning Letters Database — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
• FDA: Telehealth Companies – What to Know When Promoting Compounded Drugs — https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs

More News & Industry Reports